DKB 1902
Alternative Names: DKB-1902Latest Information Update: 27 Mar 2026
At a glance
- Originator DongKoo Bio&Pharma
- Class Antipsoriatics; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Psoriasis
Most Recent Events
- 23 Feb 2026 Phase-I clinical trials in Psoriasis in South Korea (unspecified route) prior to February 2026 (DongKoo Bio pipeline, February 2026)